L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial.

Nat Commun · 2026 · PMC13068908 · PMID 41951573

Europe PMC DOI

hedged sentences

0.1360

closest p · 2.7× alpha

0.1360

boldest claim

The sentences

a negative trendp = 0.136not close (p > 0.1)

10 ), with a negative trend between EG12 and both PFS ( r s = − 0.714, p = 0.136) and OS ( r s = − 0.371, p = 0.497).

also in 1,766 other papers

did not reach statistical significanceno p-value reported

44 (Supplementary Data 3 ) with patient characteristics matching the GLORIA inclusion criteria, PFS with NOX-A12 + BEV was longer, but did not reach statistical significance (median PFS 6.0 months; HR 0.48 (95%CI 0.16-1.15); log-rank test, p = 0.104).

also in 50,127 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.